Literature DB >> 24125979

Histopathological study of adrenocortical carcinoma with special reference to the Weiss system and TNM staging and the role of immunohistochemistry to differentiate it from renal cell carcinoma.

Santosh Kumar Mondal1, Senjuti Dasgupta, Parul Jain, Palash Kumar Mandal, Swapan Kumar Sinha.   

Abstract

BACKGROUND: Adrenocortical carcinomas (ACC) are rare tumors with an incidence of 1-2/million/year. They account for 0.05-0.2% of all malignancies. AIMS AND
OBJECTIVES: This study was aimed to evaluate the Weiss system to diagnose ACCs and to compare it with TNM staging. The role of immunohistochemistry (IHC) was also evaluated to differentiate ACC from other differential diagnoses especially, renal cell carcinoma (RCC).
MATERIALS AND METHODS: A total of 10 ACCs were included from April, 2000 to March, 2012. All the relevant information like weight, tumor size, gross features was recorded. Multiple sections were taken for histologic examination. Immunomarkers like vimentin, synaptophysin, Melan-A, calretinin, inhibin, EMA, cytokeratin, and Ki-67 were used.
RESULTS: Out of 10 cases of ACCs (diagnosed by the Weiss system), the tumors were in TNM stage I (1 case), stage II (2 cases), stage III (5 cases), and stage IV (2 cases). The Weiss score in stages I-IV was 4; 5-7; 6-8; and 5-9 respectively. ACCs were positive for vimentin, inhibin, Melan-A, calretinin and negative for EMA and cytokeratin. Proliferative index (Ki-67/MIB-1) was ≥ 20 % (20-65%).
CONCLUSION: Both the Weiss system and TNM staging are useful in predicting the malignant behavior and prognosis of ACC. Weight and tumor size, though originally not included in the Weiss system, are also important parameters. In lower stages (stages I and II), the Weiss score is low (4-7) while the score is high (6-9) when the tumor is in higher stages (stages III and IV). IHC plays a vital role to confirm the diagnosis and to exclude the possibility of RCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125979     DOI: 10.4103/0973-1482.119329

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

Review 1.  Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.

Authors:  Hironobu Sasano; Fumitoshi Satoh; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 2.  The role of microRNAs in the adrenocortical carcinomas.

Authors:  Xin Yu; Zheng Li
Journal:  Tumour Biol       Date:  2015-12-15

3.  Giant androgen-producing adrenocortical carcinoma with atrial flutter: A case report and review of the literature.

Authors:  Mircea-Florin Costache; Raluca-Elena Arhirii; Simona-Juliette Mogos; Corina Lupascu-Ursulescu; Cezara-Ioana Litcanu; Adi-Ionut Ciumanghel; Catalina Cucu; Cristina-Mihaela Ghiciuc; Antoniu-Octavian Petris; Nicolae Danila
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

Review 4.  Laparoscopic Adrenalectomy for Large Adrenocortical Carcinoma.

Authors:  Norman Oneil Machado; Hani Al Qadhi; Khalifa Al Wahaibi; Syed G Rizvi
Journal:  JSLS       Date:  2015 Jul-Sep       Impact factor: 2.172

5.  Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature.

Authors:  Weixi Wang; Rulai Han; Lei Ye; Jing Xie; Bei Tao; Fukang Sun; Ran Zhuo; Xi Chen; Xiaxing Deng; Cong Ye; Hongyan Zhao; Shu Wang
Journal:  Endocr Connect       Date:  2019-03-01       Impact factor: 3.335

6.  ADRENAL CARCINOMA IN CHILDREN: LONGITUDINAL STUDY IN MINAS GERAIS, BRAZIL.

Authors:  Nonato Mendonça Lott Monteiro; Karla Emília de Sá Rodrigues; Paula Vieira Teixeira Vidigal; Benigna Maria de Oliveira
Journal:  Rev Paul Pediatr       Date:  2018-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.